BG
TVTX icon

Bellevue Group’s Travere Therapeutics TVTX Stock Holding History

Bellevue Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$264K Buy
8,899
+5,072
+133% +$152K 0.01% 128
2025
Q4 		$146K Buy
+3,827
New +$124K ﹤0.01% 157
2025
Q3 		– Sell
-18,303
Closed -$271K – 157
2025
Q2 		$271K Sell
18,303
-4,797
-21% -$79.5K 0.01% 118
2025
Q1 		$414K Hold
23,100
– – 0.01% 122
2024
Q4 		$402K Sell
23,100
-7,900
-25% -$140K 0.01% 128
2024
Q3 		$434K Buy
+31,000
New +$323K 0.01% 133

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group's TVTX Position: Q1 2026 in Review

Bellevue Group increased its Travere Therapeutics (TVTX) stake by 133% in Q1 2026, buying an estimated $152K and bringing the position to 8,899 shares worth $264K. The position accounts for 0.01% of the portfolio, ranked #128.

Bellevue Group first reported a position in TVTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $434K in Q3 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Bellevue Group held 8,899 shares of Travere Therapeutics worth $264K as of Q1 2026.
  • Bellevue Group bought 5,072 Travere Therapeutics shares in Q1 2026, an estimated $152K.
  • Travere Therapeutics made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #128 holding.
  • Bellevue Group first reported a position in Travere Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Bellevue Group's Travere Therapeutics position peaked at $434K in Q3 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.